MedTrace Logo

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT06345014 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2024-04-04

No results posted yet for this study

Summary

This study is planned to Evaluate the Efficacy and Safety of OM-89 in Patients with Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Conditions

  • Chronic Prostatitis With Chronic Pelvic Pain Syndrome
  • Chronic Prostatitis
  • Chronic Pelvic Pain Syndrome

Interventions

DRUG

OM-89 [Uro-Vaxom® Capsule]

Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day

DRUG

OM-89 Placebo [Uro-Vaxom® Capsule Placebo]

Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)

Sponsors & Collaborators

  • OM Pharma SA

    collaborator INDUSTRY

  • AJU Pharm Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-20
Primary Completion
2025-12-30
Completion
2026-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345014 on ClinicalTrials.gov